Genetic Polymorphisms and Plasma Levels of Interleukin-22 Contribute to the Development of Nonsmall Cell Lung Cancer

被引：15

作者：

Liu, Fei ^{[1
]}

Pan, Xufeng ^{[2
]}

Zhou, Lin ^{[1
]}

Zhou, Jian ^{[3
]}

Chen, Bin ^{[3
]}

Shi, Jianxin ^{[2
]}

Gao, Wen ^{[2
]}

Lu, Liming ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Shanghai 200000, Peoples R China

[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200000, Peoples R China

[3] Fudan Univ, Eye Ear Nose & Throat Hosp, Dept Otolaryngol, Shanghai 200433, Peoples R China

来源：

DNA AND CELL BIOLOGY | 2014年 / 33卷 / 10期

基金：

中国国家自然科学基金; 上海市科技启明星计划;

关键词：

COLORECTAL-CANCER; INNATE IMMUNITY; COLON-CANCER; INFLAMMATION; RISK; IL-22; CYTOKINE; EXPRESSION; ARTHRITIS; PATHWAYS;

D O I：

10.1089/dna.2014.2432

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Interleukin (IL)-22, a relatively new member of the IL-10 family, has been implicated in inflammation and tumorigenesis. The aim of this study was to identify genetic polymorphisms in IL-22 and to measure plasma levels of IL-22 in patients with nonsmall cell lung cancer (NSCLC). Patients with NSCLC had a significantly higher frequency of IL-22 rs2227484 CT genotype (odds ratio [OR] = 1.917, 95% confidence interval [CI] 1.001-3.670, p = 0.038) and T allele (OR = 1.878, 95% CI 1.010-3.491, p = 0.049) as compared with controls. The rs2227484 genotype was associated with a 2.263-fold increased risk for advanced NSCLC (p = 0.041). Among different subtypes of NSCLC, these associations were more obvious in the adenocarcinoma. Moreover, patients with high frequencies of genotypic polymorphisms had high plasma levels of IL-22. IL-22 polymorphisms and corresponding high levels of IL-22 in plasma may contribute to the development of NSCLC, especially adenocarcinoma.

引用

页码：705 / 714

页数：10

共 32 条

[1] [Anonymous], 2011, TNM CLASSIFICATION M
[2] Inflammation and cancer: back to Virchow?
Balkwill, F
Mantovani, A
[J]. LANCET, 2001, 357 (9255) : 539 - 545
[3] Inflammation and cancer
Coussens, LM
Werb, Z
[J]. NATURE, 2002, 420 (6917) : 860 - 867
[4] Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells
Curd, L. M.
Favors, S. E.
Gregg, R. K.
[J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 168 (02) : 192 - 199
[5] Impact of interleukin-10 polymorphisms (-1082 and-3575) on the survival of patients with lymphoid neoplasms
Domingo-Domenech, Eva
Benavente, Yolanda
Gonzalez-Barca, Eva
Montalban, Carlos
Guma, Josep
Bosch, Ramon
Wang, Sophia S.
Lan, Qing
Whitby, Denise
Fernandez de Sevilla, Alberto
Rothman, Nathaniel
de Sanjose, Silvia
[J]. HAEMATOLOGICA, 2007, 92 (11) : 1475 - 1481
[6] Dubinett Steven M., 1993, Regional Immunology, V5, P232
[7] Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells
Duhen, Thomas
Geiger, Rebekka
Jarrossay, David
Lanzavecchia, Antonio
Sallusto, Federica
[J]. NATURE IMMUNOLOGY, 2009, 10 (08) : 857 - U72
[8] Interleukin 22 polymorphisms and papillary thyroid cancer
Eun, Y. G.
Shin, I. H.
Lee, Y. C.
Shin, S. Y.
Kim, S. K.
Chung, J. H.
Kwon, K. H.
[J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2013, 36 (08) : 584 - 587
[9] Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J.
Autier, P.
Boniol, M.
Heanue, M.
Colombet, M.
Boyle, P.
[J]. ANNALS OF ONCOLOGY, 2007, 18 (03) : 581 - 592
[10] CANCER IL-22: linking inflammation and cancer
Harrison, Charlotte
[J]. NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (07) : 505 - 505

← 1 2 3 4 →